SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.360 -0.360 (-7.63%)

Delayed Quote Updated: 3:59 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray ↗

June 28, 2022

The opioid crisis has raised public awareness about the dire state of pain-management options for the estimated 50 million Americans with chronic pain.

Via Benzinga

SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment ↗

June 24, 2022

SciSparc Ltd.

Via Benzinga

SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder ↗

June 23, 2022

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment

Via Benzinga

SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins ↗

June 15, 2022

JV Targets Potential Drugs for Cancers and Infectious Diseases

Via Benzinga

Central Nervous System (CNS) Therapeutics Global Market Expected to Reach $154 Billion By 2027

June 09, 2022

Palm Beach, FL – June 9, 2022 – FinancialNewsMedia.com News Commentary – The central nervous system (CNS) consists of the brain and spinal cord and brain and nervous system problems are more common and...

Via FinancialNewsMedia

Initial Positive Results For Cocaine Addiction Treatment Announced ↗

June 08, 2022

Photo by Annie Spratt on

Via Benzinga

93 Biggest Movers From Yesterday ↗

June 14, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...

Via Benzinga

SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc. ↗

June 07, 2022

SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction

Via Benzinga

SciSparc To Collaborate With Polyrizon For Brain Targeting Using Intranasal Hydrogel Systems ↗

May 31, 2022

SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology

Via Benzinga

SciSparc Announces $10M Private Offering ↗

May 27, 2022

SciSparc Ltd.

Via Benzinga

70 Stocks Moving In Monday's Mid-Day Session ↗

June 13, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...

Via Benzinga

EXCLUSIVE: SciSparc' Board To Review Potential Strategic Transactions ↗

June 09, 2022

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focused on the endocannabinoid system, plans to review potential strategic transactions.

Via Benzinga

SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial In Tourette Syndrome ↗

May 26, 2022

Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel

Via Benzinga

Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies ↗

June 08, 2022

The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs.

Via Benzinga

Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics

June 07, 2022

Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still...

Via FinancialNewsMedia

SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction ↗

June 02, 2022

SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine...

Via Benzinga

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction ↗

June 02, 2022

No dedicated treatment currently available for cocaine addiction

Via Benzinga

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).

June 02, 2022

NEW YORK, NY / ACCESSWIRE / June 2, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).

From Aegis Capital Corp.

Via AccessWire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

June 01, 2022

Good morning, investors! Busy traders are already at work this morning as we go over the biggest pre-market stock movers for Wednesday.

Via InvestorPlace

SciSparc Gets Ethics Committee Approval In Germany And Israel Sites To Conduct A Phase IIb Trial In Tourette Syndrome ↗

May 27, 2022

Image sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

70 Biggest Movers From Friday ↗

May 31, 2022

Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for...

Via Benzinga

20 Stocks Moving in Friday's Pre-Market Session ↗

May 27, 2022

Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma.

Via Benzinga

88 Biggest Movers From Yesterday ↗

May 27, 2022

Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit.

Via Benzinga

Mid-Afternoon Market Update: Dow Surges 575 Points; Apyx Medical Shares Spike Higher ↗

May 26, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 575 points on Thursday.

Via Benzinga

Mid-Day Market Update: Crude Oil Jumps Over 3%; NRx Pharmaceuticals Shares Tumble ↗

May 26, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 1.5% on Thursday.

Via Benzinga

61 Stocks Moving In Thursday's Mid-Day Session ↗

May 26, 2022

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; US Economy Contracts 1.5% In Q1 ↗

May 26, 2022

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 200 points on Thursday.

Via Benzinga

Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028

May 26, 2022

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...

Via FinancialNewsMedia

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

May 26, 2022

Good morning! We're starting off another day of trading with an overview of the biggest pre-market stock movers for Thursday!

Via InvestorPlace

20 Stocks Moving in Thursday's Pre-Market Session ↗

May 26, 2022

Gainers TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares rose 51.2% to $0.9603 in pre-market trading after dipping 18% on Wednesday.

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.